Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2025-11-04 Legal Proceedings Report
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2025
Legal Proceedings Report Classification · 100% confidence The document is a corporate announcement from BioPorto A/S regarding the status of their clinical trials for adult patients. It details delays in data collection and adjustments to the timeline for FDA submissions. This type of regulatory update, which provides information on company operations and clinical progress without being a full financial report or a specific legal filing, falls under the 'Regulatory Filings' category as a general corporate announcement.
2025-11-04 Danish
Legal Proceedings Report 2025
Legal Proceedings Report Classification · 100% confidence The document is a corporate announcement from BioPorto A/S regarding a status update on their clinical trials and FDA submission timeline. It is a regulatory announcement (Meddelelse nr. 21) issued to the market. While it discusses clinical trial progress, it does not constitute a full legal or financial report, nor is it a standalone audit or governance report. It fits the definition of a general regulatory filing (RNS) as it provides a corporate update on operational milestones.
2025-11-04 Danish
Legal Proceedings Report 2025
Legal Proceedings Report Classification · 100% confidence The document is a corporate announcement regarding the progress of a clinical study and its impact on the timeline for FDA regulatory submission. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory/corporate update regarding business operations and clinical milestones, it falls under the RNS (Regulatory Filings) category.
2025-11-04 English
Legal Proceedings Report 2025
Legal Proceedings Report Classification · 100% confidence The document is a corporate announcement from BioPorto A/S regarding the progress of its adult clinical study and the timeline for FDA regulatory submission. It is titled 'Progress Update on BioPorto’s Adult Clinical Study' and is labeled as 'Announcement no. 21'. While it provides operational updates, it does not fit into specific categories like financial results (ER/IR), governance (CGR), or share transactions (POS/DIRS). It is a general regulatory announcement regarding company operations and clinical trial status, which falls under the RNS (Regulatory Filings) category. The document also includes a link to an attachment, but the text itself serves as the primary announcement of the update.
2025-11-04 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is an official announcement from BioPorto A/S regarding their interim financial results for the second quarter of 2025. It contains substantive financial data, including revenue, EBITDA, and cash flow figures, as well as management commentary and updated guidance. Since it provides comprehensive financial performance for a period shorter than a full fiscal year (Q2 and H1 2025) and includes actual financial statements/tables, it is classified as an Interim/Quarterly Report. Q2 2025
2025-08-15 English
Earnings Release 2025
Earnings Release Classification · 100% confidence The document is a short announcement (press release) from BioPorto A/S regarding their Q2 2025 interim results. It provides a summary of financial highlights, business updates, and guidance, but explicitly includes an 'Attachment' section at the end with a link to the actual 'Q2 2025 Interim Report'. Following the 'Menu vs Meal' rule, since this is a short announcement providing a link to the full report, it is classified as a Report Publication Announcement (RPA). Q2 2025
2025-08-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.